Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Adlai Nortye Ltd ANL

Healthcare Biotechnology
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated... see more

Current News (NDAQ:ANL)

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 22, 2025

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 13, 2025

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

GlobeNewswire April 10, 2025

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

GlobeNewswire August 8, 2024

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

GlobeNewswire August 8, 2024

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

GlobeNewswire May 23, 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

GlobeNewswire May 22, 2024

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

GlobeNewswire March 29, 2024

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

GlobeNewswire November 17, 2023
View More News ››

Opinion & Analysis (NDAQ:ANL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANL)

Be the first to post on this bullboard.

Viridian Metals Inc.

Viridian Metals Inc.

Viridian Metals Inc. is a Canadian company engaged in generative exploration for critical metals, with a primary focus on ...
View More »